• Normalised revenue growth of 50.9% to $4.8 billion
• Normalised EBIT growth of 183.5% to $68.0 million
• Successful onboarding of new Chemist Warehouse supply contract

Sigma Healthcare Limited (Sigma) today announced its financial performance for the full year ended 31 January 2025 (FY25), the final full year results for Sigma as a standalone business prior to the merger with Chemist Warehouse Group (CWG), which became effective on 12 February 2025. Sigma reported normalised revenue growth of 50.9% to $4.8 billion and normalised Earnings Before Interest and Tax (EBIT) growth of 183.5% to $68.0 million, at the upper end of the guidance range previously provided. Statutory EBIT for FY25 of $21.7 million was impacted by non-recurring expenditure related to the merger with CWG and onboarding costs for the new CWG supply contract. Statutory Net Profit After Tax (NPAT) attributable to owners was further impacted by a non-cash deferred tax asset write-off as a result of the merger. Key operational highlights include the successful onboarding of the new CWG supply contract, sustained world-class operational metrics, and the securing of a new 5-year wholesale industry agreement. Sigma CEO Vikesh Ramsunder commented that the company's laser focus on building scale, driving efficiencies, simplifying the business, and enhancing margins has materially enhanced its operational performance.

Looking ahead, Sigma's management teams are focused on seamless integration and delivering long-term value to shareholders. The company has created a leading wholesaler and retail franchisor with strong growth potential in Australia and progressively internationally.